Later, Gleason et al. showed the ability of a CD16/CD19 BiKE and a CD16/CD19/CD22 TriKE to directly activate NK cells through CD16 by increasing both NK cell cytotoxicity and production of IFNγ against CLL cells [246]. The gene discussed is CD22; the disease is B-cell chronic lymphocytic leukemia.